Cargando…

A Prospective, Nonrandomized, Open‐Label Study of the Efficacy and Safety of OnabotulinumtoxinA in Adolescents with Primary Axillary Hyperhidrosis

OBJECTIVE: To evaluate the efficacy and safety of onabotulinumtoxinA in adolescents with primary axillary hyperhidrosis. METHODS: This 52‐week, multicenter, nonrandomized, open‐label study was conducted in 141 adolescents ages 12 to 17 years with severe primary axillary hyperhidrosis. Patients could...

Descripción completa

Detalles Bibliográficos
Autores principales:	Glaser, Dee Anna, Pariser, David M., Hebert, Adelaide A., Landells, Ian, Somogyi, Chris, Weng, Emily, Brin, Mitchell F., Beddingfield, Frederick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744704/ https://www.ncbi.nlm.nih.gov/pubmed/26059781 http://dx.doi.org/10.1111/pde.12620

Ejemplares similares

A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis
por: Glaser, Dee Anna, et al.
Publicado: (2019)

Botox (onabotulinumtoxinA) mechanism of action
por: Brin, Mitchell F., et al.
Publicado: (2023)

Treatment of hyperhidrosis with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Lowe, Nicholas, et al.
Publicado: (2023)

The pluripotential evolution and journey of Botox (onabotulinumtoxinA)
por: Brin, Mitchell F., et al.
Publicado: (2023)

Long‐term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44‐week open‐label extension study
por: Hebert, Adelaide A., et al.
Publicado: (2020)

Early development history of Botox (onabotulinumtoxinA)
por: Scott, Alan B., et al.
Publicado: (2023)

Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials
por: Pariser, David M., et al.
Publicado: (2018)

Pregnancy outcomes following exposure to onabotulinumtoxinA
por: Brin, Mitchell F., et al.
Publicado: (2015)

OnabotulinumtoxinA effects on trigeminal nociceptors
por: Moore, Ashley A, et al.
Publicado: (2023)

Treatment of cervical dystonia with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Jankovic, Joseph, et al.
Publicado: (2023)

Treatment of strabismus and blepharospasm with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Scott, Alan B., et al.
Publicado: (2023)

Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials
por: Hebert, Adelaide A., et al.
Publicado: (2018)

Treatment of glabellar lines with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Carruthers, Jean, et al.
Publicado: (2023)

Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review
por: Burstein, Rami, et al.
Publicado: (2020)

OnabotulinumtoxinA for Hemicrania Continua: open label experience in 9 patients
por: Miller, Sarah, et al.
Publicado: (2015)

Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Turkel, Catherine C., et al.
Publicado: (2023)

Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia
por: Marsh, Wallace A, et al.
Publicado: (2014)

Repeated OnabotulinumtoxinA Treatment of Glabellar Lines at Rest Over Three Treatment Cycles
por: Carruthers, Alastair, et al.
Publicado: (2016)

Entering the 4(th) decade of Botox (onabotulinumtoxinA): A narrative review of its development and impact on patients and medicine
por: Brin, Mitchell F.
Publicado: (2023)

A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine
por: Winner, Paul K., et al.
Publicado: (2020)

OnabotulinumtoxinA injections for atypical odontalgia: an open-label study on nine patients
por: García-Sáez, Rafael, et al.
Publicado: (2018)

Treatment of crow’s feet lines and forehead lines with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Carruthers, Alastair, et al.
Publicado: (2023)

Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine
por: Diener, H-C, et al.
Publicado: (2014)

OnabotulinumtoxinA in the treatment of neurogenic bladder
por: Gulamhusein, Aziz, et al.
Publicado: (2012)

OnabotulinumtoxinA for the treatment of overactive bladder
por: Cox, Lindsey, et al.
Publicado: (2014)

Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients
por: Eren, Ozan E., et al.
Publicado: (2020)

Treatment of pediatric spasticity, including children with cerebral palsy, with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Gormley, Mark, et al.
Publicado: (2023)

OnabotulinumtoxinA alters inflammatory gene expression and immune cells in chronic headache patients
por: Gfrerer, Lisa, et al.
Publicado: (2021)

Safety and Stability of Pulmonary Function in Patients with Decreased Respiratory Function Treated for Spasticity with OnabotulinumtoxinA
por: Ayyoub, Ziyad, et al.
Publicado: (2020)

Safety, Pharmacodynamic Response, and Treatment Satisfaction With OnabotulinumtoxinA 40 U, 60 U, and 80 U in Subjects With Moderate to Severe Dynamic Glabellar Lines
por: Joseph, John H, et al.
Publicado: (2022)

Cognitive effects of onabotulinumtoxinA in chronic migraine
por: Ho, Susan, et al.
Publicado: (2020)

OnabotulinumtoxinA: Still the Present for Chronic Migraine
por: Baraldi, Carlo, et al.
Publicado: (2023)

Limited Systemic Exposure with Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis
por: Pariser, David M., et al.
Publicado: (2021)

Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study
por: Winner, Paul K., et al.
Publicado: (2019)

Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons
por: Melo-Carrillo, Agustin, et al.
Publicado: (2020)

Pregnancy Outcomes in Patients Exposed to OnabotulinumtoxinA Treatment: A Cumulative 29-Year Safety Update
por: Brin, Mitchell F., et al.
Publicado: (2023)

Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine
por: Russell, Michael Bjørn
Publicado: (2011)

OnabotulinumtoxinA for chronic migraine: a critical appraisal
por: Gooriah, Rubesh, et al.
Publicado: (2015)

The Role of OnabotulinumtoxinA in Urology: What Is the Next Step?
por: Moon, Hong Sang
Publicado: (2015)

OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine
por: Frampton, James E., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_b4u1nnvg5ne5dla9lol0e9pvhv